AKT1 and neoplasm: In combination with the previous finding that down-regulation of MUC1 would inhibit drug resistance in tumor cells, our data indicated that the level of MUC1 was critical in determining the efficiency of anti-tumor drugs targeting PI3K/Akt/mTOR signaling axis.